Purpose: To assess the ability of ChatGPT to answer common patient questions regarding hip arthroscopy, and to analyze the accuracy and appropriateness of its responses.
Methods: Ten questions were selected from well-known patient education websites, and ChatGPT (version 3.5) responses to these questions were graded by 2 fellowship-trained hip preservation surgeons. Responses were analyzed, compared with the current literature, and graded from A to D (A being the highest, and D being the lowest) in a grading scale on the basis of the accuracy and completeness of the response. If the grading differed between the 2 surgeons, a consensus was reached. Inter-rater agreement was calculated. The readability of responses was also assessed using the Flesch-Kincaid Reading Ease Score (FRES) and Flesch-Kincaid Grade Level (FKGL).
Results: Responses received the following consensus grades: A (50%, n = 5), B (30%, n = 3), C (10%, n = 1), D (10%, n = 1). Inter-rater agreement on the basis of initial individual grading was 30%. The mean FRES was 28.2 (± 9.2 standard deviation), corresponding to a college graduate level, ranging from 11.7 to 42.5. The mean FKGL was 14.4 (±1.8 standard deviation), ranging from 12.1 to 18, indicating a college student reading level.
Conclusions: ChatGPT can answer common patient questions regarding hip arthroscopy with satisfactory accuracy graded by 2 high-volume hip arthroscopists; however, incorrect information was identified in more than one instance. Caution must be observed when using ChatGPT for patient education related to hip arthroscopy.
Clinical Relevance: Given the increasing number of hip arthroscopies being performed annually, ChatGPT has the potential to aid physicians in educating their patients about this procedure and addressing any questions they may have.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.arthro.2024.06.017 | DOI Listing |
J Neurosurg Spine
January 2025
2Anesthesiology, University of Miami Miller School of Medicine, Miami, Florida.
Objective: Awake, endoscopic spinal fusion has been utilized as an ultra-minimally invasive surgery technique to accomplish the goals of spinal fixation, fusion, and disc height restoration. While many techniques exist for this approach, this series represents a single institution's experience with a large cohort and the evolution of this method.
Methods: The medical records of a consecutive series of 400 patients treated over a 10-year period were retrospectively reviewed.
Otol Neurotol
February 2025
Department of Radiology, Yale School of Medicine, New Haven, CT.
Background: Vestibular schwannoma (VS) is a common intracranial tumor that affects patients' quality of life. Reliable imaging techniques for tumor volume assessment are essential for guiding management decisions. The study aimed to compare the ABC/2 method to the gold standard planimetry method for volumetric assessment of VS.
View Article and Find Full Text PDFEur Thyroid J
January 2025
D Yabe, Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine Faculty of Medicine, Kyoto, Japan.
Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt thyroid irAEs ranged 8.9-22.
View Article and Find Full Text PDFBlood
January 2025
Stanford University Medical Center, Stanford, California, United States.
Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy limited by graft-versus-host disease (GVHD). In preclinical studies and early-phase clinical studies enrichment of donor regulatory T cells (Tregs) appears to prevent GVHD and promote healthy immunity.We enrolled 44 patients on an open-label, single-center, phase 2 efficacy study investigating if a precision selected and highly purified Treg cell therapy manufactured from donor mobilized peripheral blood improves one-year GVHD-free relapse free survival (GRFS) after myeloablative conditioning (trial NCT01660607).
View Article and Find Full Text PDFPatients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!